Lillian Xiang Li

Analytical and CMC development

Role: Staff Scientist, Protein Downstream Process Development at Vaxcyte
Location: Mountain View, CA, US
LinkedIn followers: 500 followers

About Lillian Xiang Li

Ph.D scientist with 10+ years industry and government agency experience for a variety of healthcare/consumer/ pharmaceutical products. • Extensive experience in working with CMO/CRO, ICH/FDA/ISO/GLP guidelines, IND, ANDA/DNA, CMC/ cGMP, method development/validation and transfer.• Cross-functional leadership experience spanning analytical chemistry, formulation, process engineering, regulatory and manufacture. • Leads by example and builds a culture of trust within the team. Good at influencing and engaging all stakeholders for results.

Experience

Staff Scientist, Protein Downstream Process Development
Vaxcyte
Feb 2024 — Present · San Carlos, CA, US
Analytical lead for in-process development for protein-conjugate vaccines.

Education

Fudan University
Bachelor of Science (BS), Chemistry
2001 — 2005
Pennsylvania State University
Ph.D, Physical/Analytical Chemistry
2005 — 2010

Skills

Fluorescence
Uv-Vis
Analytical Chemistry
Ir
Nmr
Mass Spectrometry
Microscopy
Science
Chromatography
Hplc
Polymers
X-Ray
Chemistry
Nir
Physical Chemistry
Cgmp Practices
Chemometrics
Icp
Fluorescence Spectroscopy
Characterization
Spectroscopy
Andas
Purification

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
l••••••••@vaxcyte.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Vaxcyte

Biotechnology Research · 580 employees · Founded 2013 · San Carlos, California, United States

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

vaxcyte.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Lillian Xiang Li

Experience

Staff Scientist, Protein Downstream Process Development

Education

Fudan University

Pennsylvania State University

Skills

Find verified contacts for anyone on LinkedIn